Scientists have identified a genetic adaptation found in animals living on the Tibetan Plateau that could offer a novel treatment strategy for nerve damage in humans. The discovery, published in the journal Neuron, reveals how a mutation in the Retsat gene enhances the brain's ability to rebuild myelin, the protective coating around nerve fibers essential for proper nervous system function.
Researchers from Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine conducted experiments showing that this genetic variant, naturally selected in yaks and Tibetan antelopes to survive in thin air, may help restore myelin damage caused by cerebral palsy, multiple sclerosis, and age-related vascular disorders.
Myelin damage represents a fundamental problem in several neurological conditions. When the protective sheath surrounding nerve fibers deteriorates, electrical signals traveling through the brain and spinal cord slow down or fail entirely. Low oxygen during early development can trigger this damage in newborns. In adults, MS attacks myelin through autoimmune mechanisms, while reduced blood flow associated with aging contributes to conditions like cerebral small vessel disease and vascular dementia.
The research team tested the Retsat mutation by exposing newborn mice to severely low-oxygen conditions mimicking altitudes above 13,000 feet. Mice carrying the mutation outperformed control animals in learning, memory, and social behavior tests. Brain tissue analysis revealed these mice maintained significantly higher myelin levels around their nerve fibers.
When the scientists induced MS-like damage in mice with the mutation, myelin recovery happened faster and more completely than in normal mice. Brain tissue from these animals contained substantially more mature oligodendrocytes, the specialized cells that manufacture myelin.
The mechanism behind this advantage centers on a vitamin A derivative called ATDR. Mice with the Retsat mutation produced elevated levels of this metabolite in their brains. The mutation enhances enzymes that convert vitamin A into active forms that support oligodendrocyte growth and maturation, ultimately enabling faster myelin reconstruction.
What makes this finding particularly promising is that ATDR already circulates naturally in every human body. When researchers administered ATDR to mice suffering from MS-like conditions, the animals showed reduced disease severity and improved motor function.
Current MS treatments focus primarily on suppressing immune system attacks on myelin. Corresponding author Liang Zhang noted that this discovery suggests an alternative pathway. "ATDR is something everyone already has in their body," Zhang explained. "Our findings suggest that there may be an alternative approach that uses naturally occurring molecules to treat diseases related to myelin damage."
The work demonstrates how evolution has equipped organisms with biological solutions to environmental stress. High-altitude animals developed the Retsat mutation to preserve brain health in chronically oxygen-depleted conditions. Rather than inventing entirely new therapeutics, researchers may be able to leverage these naturally occurring pathways that the human body already possesses.
The next phase of research will likely involve testing whether boosting ATDR levels could benefit human patients with MS and related conditions. If successful, this approach would represent a fundamentally different strategy from current immune-suppressing therapies, potentially offering patients new options for managing myelin-damaging diseases.
Author Jessica Williams: "Nature keeps handing us answers we've overlooked for centuries, and this Retsat story is exactly the kind of elegant biological solution that makes you wonder what else we're missing."
Comments